Jeffrey A. Ferrell – Managing Partner

Jeffrey A. Ferrell, Partner

Mr. Ferrell founded Athyrium in 2008 and currently serves as the firm’s Managing Partner. Mr. Ferrell has substantial investment experience in the life sciences sector across a wide range of asset classes and transaction structures.

Prior to forming Athyrium, Mr. Ferrell served in a number of capacities at Lehman Brothers from 2001 to 2008. Most recently he oversaw life sciences investments for Global Trading Strategies, a principal investment group within Lehman. The ~$400 million portfolio was invested in equity, debt and structured investments of both public and private companies. Representative investments include: Sequenom, Bioenvision (acquired by Genzyme), Jazz Pharmaceuticals, Orthovita (acquired by Stryker), Nektar Therapeutics, ISTA Pharmaceuticals, and Lpath.

Prior to joining Global Trading, Mr. Ferrell was a Vice President in Lehman Brothers’ Private Equity division focused on life sciences investments. Investments that Mr. Ferrell worked on include: Auxilium Pharmaceuticals, Jazz Pharmaceuticals, KaloBios, and Fluidigm.

Prior to joining Lehman in 2001, he was a Principal at Schroder Ventures Life Sciences (SVLS) based in Boston. While at Schroder, investments Mr. Ferrell was involved with include: EyeTech Pharmaceuticals, Versicor/Vicuron, Achillion, Allos Therapeutics, and GelTex Pharmceuticals.

Mr. Ferrell graduated with an A.B. in Biochemical Sciences from Harvard College. Mr. Ferrell currently serves on the Board of Directors of Lpath and Progenity.